Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/201145
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Silva, Rui | - |
dc.contributor.author | Colom Codina, Helena | - |
dc.contributor.author | Bicker, Joana | - |
dc.contributor.author | Almeida, Anabela | - |
dc.contributor.author | Silva, Ana | - |
dc.contributor.author | Sales, Francisco | - |
dc.contributor.author | Santana, Isabel | - |
dc.contributor.author | Falcão, Amílcar | - |
dc.contributor.author | Fortuna, Ana | - |
dc.date.accessioned | 2023-07-25T10:54:06Z | - |
dc.date.available | 2023-07-25T10:54:06Z | - |
dc.date.issued | 2023-06-10 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | http://hdl.handle.net/2445/201145 | - |
dc.description.abstract | Perampanel is a promising antiepileptic drug (AED) for refractory epilepsy treatment due to its innovative mechanism of action. This study aimed to develop a population pharmacokinetic (PopPK) model to be further used in initial dose optimization of perampanel in patients diagnosed with refractory epilepsy. A total of seventy-two plasma concentrations of perampanel obtained from forty-four patients were analyzed through a population pharmacokinetic approach by means of nonlinear mixed effects modeling (NONMEM). A one-compartment model with first-order elimination best described the pharmacokinetic profiles of perampanel. Interpatient variability (IPV) was entered on clearance (CL), while the residual error (RE) was modeled as proportional. The presence of enzyme-inducing AEDs (EIAEDs) and body mass index (BMI) were found as significant covariates for CL and volume of distribution (V), respectively. The mean (relative standard error) estimates for CL and V of the final model were 0.419 L/h (5.56%) and 29.50 (6.41%), respectively. IPV was 30.84% and the proportional RE was 6.44%. Internal validation demonstrated an acceptable predictive performance of the final model. A reliable population pharmacokinetic model was successfully developed, and it is the first enrolling real-life adults diagnosed with refractory epilepsy. | - |
dc.format.extent | 16 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics15061704 | - |
dc.relation.ispartof | Pharmaceutics, 2023, vol. 15, num. 6 | - |
dc.relation.uri | https://doi.org/10.3390/pharmaceutics15061704 | - |
dc.rights | cc by (c) Silva, Rui et al, 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Epilèpsia | - |
dc.subject.classification | Farmacologia | - |
dc.subject.classification | Portugal | - |
dc.subject.other | Epilepsy | - |
dc.subject.other | Pharmacology | - |
dc.subject.other | Portugal | - |
dc.title | Population Pharmacokinetic Analysis of Perampanel in Portuguese Patients Diagnosed with Refractory Epilepsy | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-07-13T08:58:10Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37376153 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
pharmaceutics-15-01704-v2.pdf | 6.11 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License